


RESEARCH ARTICLE

Open Access

Collusion of α -Synuclein and A β aggravating co-morbidities in a novel prion-type mouse model



Grace M. Lloyd^{1,2}, Jess-Karan S. Dhillon^{1,2}, Kimberly-Marie M. Gorion^{1,2}, Cara Riffe^{1,2}, Susan E. Fromholt^{1,2}, Yuxing Xia^{1,2}, Benoit I. Giasson^{1,2,3*}  and David R. Borchelt^{1,2,3*}

Abstract

Background: The misfolding of host-encoded proteins into pathological prion conformations is a defining characteristic of many neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Lewy body dementia. A current area of intense study is the way in which the pathological deposition of these proteins might influence each other, as various combinations of co-pathology between prion-capable proteins are associated with exacerbation of disease. A spectrum of pathological, genetic and biochemical evidence provides credence to the notion that amyloid β (A β) accumulation can induce and promote α -synuclein pathology, driving neurodegeneration.

Methods: To assess the interplay between α -synuclein and A β on protein aggregation kinetics, we crossed mice expressing human α -synuclein (M20) with APP^{swe}/PS1^{dE9} transgenic mice (L85) to generate M20/L85 mice. We then injected α -synuclein preformed fibrils (PFFs) unilaterally into the hippocampus of 6-month-old mice, harvesting 2 or 4 months later.

Results: Immunohistochemical analysis of M20/L85 mice revealed that pre-existing A β plaques exacerbate the spread and deposition of induced α -synuclein pathology. This process was associated with increased neuroinflammation. Unexpectedly, the injection of α -synuclein PFFs in L85 mice enhanced the deposition of A β ; whereas the level of A β deposition in M20/L85 bigenic mice, injected with α -synuclein PFFs, did not differ from that of mice injected with PBS.

Conclusions: These studies reveal novel and unexpected interplays between α -synuclein pathology, A β and neuroinflammation in mice that recapitulate the pathology of Alzheimer's disease and Lewy body dementia.

Keywords: Alzheimer's disease, A β , Lewy body dementia, α -Synuclein, Prion-like propagation

* Correspondence: bgiasson@ufl.edu; drb1@ufl.edu

¹Department of Neuroscience, College of Medicine, University of Florida, Gainesville, Florida 32610, USA

Full list of author information is available at the end of the article



© The Author(s). 2021 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Background

Many proteins can enter an amyloidogenic state, wherein a protein, prompted by the surrounding milieu, cellular signaling, or even another protein, adopts a β -sheet structure. These β -sheets can stack upon one another into fibrils stabilized by hydrogen bonding [1] and with time, may accumulate progressively into larger aggregates. Proteins that are able to pass this alternative structure onto naïve copies of themselves through conformational templating are termed prions and are considered to be transmissible agents [2]. Prions, and prion-like proteins, are areas of intense research as their mechanisms of misfolding and propagation, resulting in progressive amyloid accumulation, can lead to neurodegeneration. Neurodegenerative diseases are histologically hallmarked by the fibrous lesions formed from aggregated amyloids, and often exhibit co-pathology of multiple priogenic proteins [3] resulting in a spectrum of proteinopathies categorized by their clinical and histopathological features, rather than just the type of aggregated protein.

Two of the most common forms of age-related neurodegenerative disorders, Alzheimer's disease (AD) and Parkinson's disease (PD), which canonically exhibit accumulations of amyloid β (A β) and α -synuclein (α Syn) respectively, often exhibit co-pathology of these proteins and represent keystone components on the spectrum of neurodegenerative disorders [4–18]. Lewy body dementia (LBD) oscillates between these disorders, exhibiting both A β and α Syn pathology [11, 15, 19–23]. A significant percentage (20–40%) of patients with PD or LBD present with both abundant α Syn inclusions and A β deposits [4–11]. Moreover, α Syn inclusions are frequently observed in brains from patients with sporadic and familial AD, where genetic defects in the *APP*, *PSEN1* and *PSEN2* genes directly affect biological pathways that promote A β deposition [12, 24–27].

These pathological findings, and the overlap of clinical symptoms between AD and PD patients [13–16, 18, 28–31], suggest that A β and α Syn can collude to induce and enhance pathogenesis, possibly due to their infectious nature as priogenic proteins. In an effort to illuminate the interactions between the pathogenic forms of these proteins, we developed a mouse model in which the deposition of A β was intrinsically driven by transgenesis, and used intracerebral prion-like seeding to induce α Syn inclusion pathology, as has been previously shown effective in other models of neurodegeneration [32–37]. We used APPswe/PS1dE9 (L85) as our A β mouse model; this model develops A β deposition by 4–6 months of age [38, 39]. To model interactions between human A β and human α Syn, we crossed the L85 mice to the M20 model, which expresses WT human α Syn [40, 41]. M20 mice do not present with an aberrant

phenotype or display any α Syn pathology during their normal lifespan [40, 41], but develop extensive α Syn pathology following intracerebral injection of α Syn preformed fibrils (PFFs) [36, 37]. Using this model, we investigated the impact that pre-existing A β pathology has on the induction of α Syn inclusion pathology by injection of PFF, how α Syn pathology in turn alters A β plaque formation, and the interplay of neuroinflammation induced by these pathologies.

Methods

Mouse lines

All procedures were performed according to the National Institute of Health Guide for the Care and Use of Experimental Animals and were approved by the University of Florida Institutional Animal Care and Use Committee. Mice were housed in a stable environment with a 12-h light/dark cycle and access to food and water ad libitum. Transgenic mice expressing WT human α Syn (line M20), were generated using the mouse PrP vector (MoPrP.Xho) to drive expression [40, 41], and were maintained on a C57BL/6J background as hemizygous mice (M20^{+/-}) by mating with non-transgenic (nTg) C57BL/6J (Charles River) mice. APPswePS1dE9 double-transgenic mice (L85) express a chimeric mouse/human amyloid precursor protein (APP), containing known familial mutations in APP (KM670/671NL) and a human presenilin-1 variant carrying the exon 9 deletion, [38, 39]. Both transgenes were expressed together under control of the mouse prion protein promoter (MoPrP.Xho), directing expression predominantly in neurons but also in astrocytes of the CNS [42]. To generate all of the mice used in these studies, M20^{+/-} and L85^{+/-} mice were mated to produce non-transgenic (nTg), M20^{+/-} (M20), L85^{+/-} (L85) and M20^{+/-}/L85^{+/-} (dTg) litter mates.

Recombinant human α Syn expression, purification and fibril formation

The pRK172 bacterial expression vector containing the cDNA encoding WT human α Syn was transformed into BL21 (DE3)/RIL *E. coli* (*E. coli*; Agilent Technologies) and recombinant α Syn was purified from *E. coli* using size exclusion chromatography followed by anion exchange as previously described [43, 44]. Protein concentrations were determined by bicinchoninic acid assay using bovine serum albumin as the protein standard.

To generate PFFs for injection, recombinant human α Syn protein [5 mg/ml in sterile phosphate buffered saline (PBS)] was incubated at 37 °C with constant shaking at 1050 RPM (Thermomixer R, Eppendorf) for > 48 h. Fibril formation was monitored by K114 [(trans, trans)-1-bromo-2,5-bis-(4-hydroxy) styrylbenzene] fluorometry as previously described [45]. Fibrils were diluted to 2 mg/ml in sterile PBS and sonicated in a water bath for 2

h. Sonicated fibrils were then aliquoted, stored at -80°C and thawed when required. Each experiment in this study was performed using PFFs from the same preparation, in order to limit batch to batch variation.

Stereotaxic brain injections of αSyn PFFs

nTg, M20^{+/-}, L85^{+/-} and dTg mice were injected unilaterally into the hippocampus (coordinates from Bregma: anterior/posterior -2.2 mm, lateral -1.6 mm, dorsal/ventral -1.2 mm) at 6 months of age as previously described [34]. For injection, 2 μL of solution (sterile PBS), containing 4 μg of PFFs was utilized. An additional set of mice in each cohort were injected in the same location with 2 μL of vehicle (sterile PBS) as negative controls. Mice were aged until 8 or 10 months, then were sacrificed for histologic analysis.

Tissue processing

At designated time points, mice were euthanized with CO_2 and perfused with a heparin/PBS solution. For histopathology, brains and spinal cords were harvested and fixed in 70% EtOH/150 mM NaCl, paraffin embedded, and sectioned as previously described [46]. For biochemical analysis, some brains were snap frozen on dry ice and stored at -80°C for tissue analysis. The number of animals analyzed and their genotypes, are summarized in Table 1.

Immunohistochemistry and immunofluorescence

Tissue sections were rehydrated with xylenes and graded, 100–70% ethanol steps [47], followed with only heat-induced epitope retrieval (HIER) in a steam bath for 60 min in water with 0.05% Tween-20, unless otherwise indicated. After antigen retrieval, sections were washed in running deionized H_2O for 15 min. Endogenous peroxidase was quenched by incubating sections in 1.5% hydrogen peroxide/0.005% Triton-X-100 diluted in PBS, pH 7.4 (Invitrogen) for 10 min. Sections were then rinsed in running deionized H_2O for 15 min, washed three times for 5 min in 0.1 M Tris, pH 7.6, and then blocked in 2% fetal bovine serum (FBS)/0.1 M Tris, pH 7.6 solution for 5 min. Slides were incubated with primary antibodies diluted in blocking solution and stored overnight in 4°C . Primary antibodies and dilution factors are listed in Tables 2 and 3.

After overnight incubation, primary antibody was removed from slides with a quick rinse, then incubated

with agitation for 5 min in 0.1 M Tris, pH 7.6, three times. Tissue sections were incubated for 1 h with either goat anti-rabbit or anti-mouse biotinylated IgG (Vector Laboratories; Burlingame, CA) in 0.1 M Tris, pH 7.6/2% FBS at room temperature. Secondary antibody was rinsed three times with 0.1 M Tris, pH 7.6 for 5 min. Sections were then incubated with an avidin-biotin complex (ABC) solution (Vectastain ABC Elite kit; Vector Laboratories, Burlingame, CA) for 1 h at room temperature, then rinsed again, three times, with 0.1 M Tris, pH 7.6, for 5 min. Sections were developed using chromogen 3,3'-diaminobenzidine (DAB kit; KPL, Gaithersburg, MD) and counterstained using hematoxylin (Sigma Aldrich, St. Louis, MO). For $\text{A}\beta$ immunohistochemistry (IHC), optimized epitope unmasking and antigen retrieval was performed using methods previously described [54]. Succinctly, sections were treated with 70% formic acid for 10 min at room temperature, treated in a steam bath in 0.05% Tween-20 and modified citrate buffer (Target Retrieval Solution Citrate pH 6; Agilent, Santa Clara, CA) for 30 min, and cooled to room temperature for 30 min. Rinsing, blocking and primary dilution steps remain congruent with standard methods. For secondary antibody application, ImmPRESS polymer secondary antibody (Vector Laboratories; Burlingame, CA) was applied to sections for 90 min at room temperature; DAB solution was warmed to 37°C prior to application. For ionized calcium binding adaptor molecule 1(Iba1) IHC, sections were incubated in formalin for 48 h after rehydration. Sections were then rinsed in water for 10 min. HIER was performed for 30 min using modified citrate buffer (Target Retrieval Solution Citrate pH 6; Agilent, Santa Clara, CA), then treated with 70% formic acid for 10 min. Rinsing, blocking and primary dilution steps remain the same as indicated above. For secondary antibody application, ImmPRESS polymer secondary antibody (Vector Laboratories; Burlingame, CA) was diluted in a 1:10 ratio with the standard secondary antibody solution described above. The remainder of this protocol is same as described above.

Double labeling with rabbit anti-neurofilament light chain (NFL) (C28E10; Cell Signaling Technology) followed the rehydration steps described above, with HIER in a steam bath for 60 min using modified citrate buffer. Rinsing, blocking and primary dilution steps remain the same as indicated above. For secondary antibody application, the previously described DAB reaction

Table 1 Summary of mice used for studies. Organized by genotype, sex and injection cohort used in the studies

Injection Type/Age	nTg		M20		L85		dTg	
PBS/10 months (4 m.p.i.)	4 M	4 F	4 M	2 F	4 M	4 F	2 M	4 F
PFF/8 months (2 m.p.i.)	4 M	4 F	4 M	4 M	4 M	4 F	4 M	4 F
PFF/10 months (4 m.p.i.)	5 M	8 F	4 M	8 F	4 M	6 F	5 M	6 F

Table 2 List of antibodies used with dilutions and conditions

Immunocytochemistry /Immunofluorescence				
1°Antibody (1°Ab)	Dilution	Specificity	Host	Antigen Retrieval
81A	1:1000	αSyn at pSer129	Mouse	Water boil w/ 0.05% Tween
2H6	1:5000	αSyn (2–21)	Mouse	Water boil w/ 0.05% Tween
EP1536Y	1:1000	αSyn at pSer129	Rabbit	Water boil w/ 0.05% Tween
5G4	1:1000	oligomeric, aggregated αSyn (44–57)	Mouse	Water boil w/ Citrate/70% Formic acid
AB5	1:1000	Aβ	Mouse	70% Formic acid/Water boil w/ Citrate
12F4	1:500	Aβ _{1–42}	Mouse	70% Formic acid/Water boil w/ Citrate
33.1.1	1:500	Aβ _{1–16}	Mouse	70% Formic acid/Water boil w/ Citrate
13.1.1	1:800	Aβ _{1–40}	Mouse	70% Formic acid/Water boil w/ Citrate
GFAP (from Dako)	1:2000	Astrocytes, glial cells	Rabbit	Water boil w/ 0.05% Tween
Iba1	1:1000	Macrophages, microglia	Rabbit	Water boil w/ Citrate/70% Formic acid
p62	1:2000	Sequestosome1	Rabbit	Water boil w/ 0.05% Tween
NFL	1:500	NFL	Rabbit	Water boil w/ Citrate
Western blotting				
1°Antibody (1°Ab)	Dilution	Epitope	Host	
94-3A10	1:1000	human and mouse αSyn (130–140)	Mouse	
6E10	1:1000	Aβ	Mouse	
15-4A5	1:1000	human αSyn (120–125)	Mouse	
C4	1:1000	actin	Mouse	

was first completed. Tissue was then rinsed and ImmPRESS anti-rabbit conjugated to alkaline phosphatase (Vector Laboratories) was applied for 90 min. After washes, sections were incubated in 0.1 M Tris, pH 8.45 for 30 min, and labeling was visualized with Vector Red substrate (Vector Laboratories). Tissue sections were then counterstained with hematoxylin, dehydrated and mounted as described above.

For immunofluorescence analysis (IFA), antigen retrieval was performed using standard methods with the following modifications: quenching endogenous peroxidase was not performed, primary antibody was diluted in 5% skim milk/TBS. Following incubation overnight with primary antibodies, and previously described rinsing method, tissue sections were incubated with Alexa Fluor 488 or 594-conjugated secondary antibodies (Invitrogen, USA) for 2 h at room temperature, then washed in 0.1 M Tris, pH 7.6 for 20 min. To reduce background lipofuscin autofluorescence, sections were incubated in a 0.3% Sudan Black/70% ETOH solution for 10 min at room temperature, then rinsed in deionized H₂O for 5 min. In order to stain the nuclei, slides were incubated for 5 min in 4,6 diamidino-2-phenylindole (DAPI) stain (1 μg/ml) diluted in PBS. Slides were then washed in deionized H₂O for 5 min and cover-slipped using Fluoromount-G (Southern Biotech).

Semi-quantification and digital analysis of pathology

All IHC sections were digitally scanned using an Aperio ScanScope CS instrument (40× magnification; Aperio Technologies Inc., Vista, CA, USA), and images of representative areas of pathology were captured using the ImageScope software (40× magnification, Aperio Technologies Inc.). Tissue sections stained with the following antibodies: 81A, p62 and AB5, were semi-quantified via manual counting of positively stained inclusions/plaques by two blinded observers at 20x objective. For quantification of gliosis, GFAP and Iba1 stained sections were analyzed using Aperio ImageScope. Regions of interest (ROIs) were selected in the retrosplenial cortex, CA1 of the hippocampus and amygdala/entorhinal cortex and quantified separately. A modified version of ImageScope's Positive Pixel Count algorithm v9 was used to measure the intensity of individual stains within the selected ROI, classifying them as either 'Weak', 'Medium', or 'Strong'. In order to maximize pathology detection and minimize background, statistical analysis was completed using only values classified as 'Strong' positivity. For quantification of αSyn pathology, 81A and 5G4 stained sections were analyzed using a modified version of ImageScope's Color Deconvolution algorithm v9, tailored to each staining, and slides were scored based on the quantified optical density (OD) analysis of the immunoreactive area (IRA) for the DAB color channel. For

Table 3 Key Resources

Key Resources Table		
Antibodies	Source	Identifier
pSer129 αSyn	B. Giasson University of Florida College of Medicine; Florida; USA	81A [48]
2–21 mouse and human αSyn	B. Giasson University of Florida College of Medicine; Florida; USA	2H6 [49]
130–140 mouse and human αSyn	B. Giasson University of Florida College of Medicine; Florida; USA	94-3A10 [49]
120–125 human αSyn	B. Giasson University of Florida College of Medicine; Florida; USA	15-4A5 [49, 50]
pSer129 αSyn	Abcam	EP1536Y [51]
1–16 Aβ	T. Golde University of Florida College of Medicine; Florida; USA	Ab5 [52]
4–10 Aβ; APP	Biolegend	6E10; Cat # 803003
x-42 Aβ specific	EMD Millipore Corporation, Temecula, CA	12F4; Lot: 3270770
x-40 A specific	T. Golde University of Florida College of Medicine; Florida; USA	13.1.1 [52]
1–16 Aβ	T. Golde University of Florida College of Medicine; Florida; USA	33.1.1 [52]
GFAP	Dako, Carpinteria, CA	GFAP Dako Cat # Z0334
p62/sequestosome1	ProteinTech, Rosemont, IL	
NFL	Cell Signaling	Cat# C28E10
5G4	Fisher Scientific	Cat # MABN389MI [53]
Actin	Fisher Scientific	Clone C4; Cat# MAB1501MI
Experimental Models: Organisms/Strains		
Cohort Name	Source	N
Line 85	D. Borchelt University of Florida College of Medicine; Florida; USA	M:12; F:14
M20	B. Giasson University of Florida College of Medicine; Florida; USA	M:12; F:14
dTg	D. Borchelt University of Florida College of Medicine; Florida; USA	M:11; F:14
C3H/BL6 (nTg)	Charles River	M:13; F:16
Chemicals, peptides, and Recombinant Proteins		
Human α-synuclein PFFs	This manuscript	N/A
Software and Algorithms		
Prism 7	GraphPad	

analysis and input into heatmaps, scores were normalized by setting the highest score from all cohorts as the maximum value. IFA sections were visualized using an Olympus BX51 microscope mounted with a DP71 Olympus digital camera to capture images at 20x/40x magnification. Representative images were adjusted for white/black values; brightness/contrast corrections were applied identically on captured images within each figure using Adobe Photoshop CS3 (Adobe Systems, San Jose, CA, USA). All raw files and algorithms are available upon request.

Western blot analysis

Whole mouse brains were quickly frozen on dry ice and stored at -80°C before extraction. Tissue from eight mice were thawed, individually sonicated in 4% SDS/50 mM Tris, pH 7.6, and heated for 10 min at 90°C . Protein concentrations for all fractions were determined using the BCA assay (Pierce, Waltham, MA, USA), using bovine serum albumin as a standard. Samples were

normalized for total protein content and SDS-containing sample buffer was added to samples, which were then further heated for 10 min at 90°C . Protein samples were separated on SDS-polyacrylamide gels (8% or 15%) and transferred electrophoretically onto $0.22\ \mu\text{m}$ nitrocellulose membranes (Bio-Rad, Hercules, CA). Membranes were blocked in 5% non-fat milk in Tris-buffered saline, pH 7.6 (TBS) for 1 h at room temperature, then incubated in primary antibodies (detailed in Table 2) diluted in 5% non-fat milk/TBS block solution overnight in 4°C . After incubation, membranes were rinsed with agitation in TBS for 5 min, repeated eight times. Membranes were then incubated with goat anti-mouse secondary antibody conjugated to horseradish peroxidase (Jackson Immuno Research Labs, Westgrove, PA), diluted 1:1000 in 5% non-fat milk/TBS for 2 h at room temperature. Protein band signal was detected with Western Lightning-Plus ECL reagents (PerkinElmer, Waltham, MA) and chemiluminescence imaging (PXi, Syngene, Frederick, MD).

Statistical analysis

The number of samples or animals (n) analyzed for each experiment, the statistical analysis performed and the *p*-values for all results are reported in the Table 1, Figures, and/or Figure Legends. Data was tested for normality using D'Agostino-Pearson test. A Two-Way ANOVA was used to compare quantified IHC results of PBS and α Syn PFF-injected animals between each cohort; Holm-Sidak test was used to correct for multiple comparisons and each *P* value was multiplicity adjusted. Family-wise significance was set at 0.05. Statistical analysis was performed using Prism software (GraphPad Software, San Diego, CA, USA). Data are presented as mean \pm SEM, and level of significance was set at *p* < 0.05.


Results


Antecedent A β pathology leads to exacerbation of induced α Syn inclusion formation

To investigate the interplay between the formation of α Syn inclusion pathology and A β deposition, we crossed M20 transgenic mice [40, 41] with L85 mice [38, 39]. Mice harboring the M20 α Syn transgenes and the L85 APP_{swe}/PS1_{dE9} transgene complexes are hereinafter referred to as 'dTg'. Overexpression of human α Syn in M20 and dTg mice was confirmed by western blot analysis on whole brain lysate using antibodies specific for human α Syn (15-4A5) and total human and mouse α Syn (94-3A10), respectively (Fig. 1). Similarly, overexpression of APP in L85 and dTg mice was established by western blotting with 6E10 antibody (Fig. 1). Importantly, the levels of overexpression of human α Syn and APP in the original respective mouse line compared to nTg mice was similar (Fig. 1).

Human α Syn PFFs and PBS (control) were stereotactically injected in the hippocampus of 6-month-old mice which were then aged to 8 or 10 months. At 6 months of age, L85 mice have substantial A β deposition that would be expected to continue to worsen with age [55, 56]. The number of mice in each cohort are detailed in Tables 1 and 3 and are indicated in each figure legend. nTg and L85 mouse cohorts, which only express endogenous mouse α Syn, did not present with any α Syn inclusion pathology even after the intracerebellar injection of 4 μ g of human α Syn PFFs (Supplementary Figure 1). However, both dTg and M20 mice injected with the same PFF preparations exhibited widespread α Syn pathology throughout hippocampal and cortical regions (Fig. 2A). Consistent with previous findings [37], PBS-injection did not elicit α Syn pathology in any cohort, including dTg (Fig. 2B). Analysis with pSer129 antibody 81A, and aggregate specific α Syn antibody, 5G4, revealed that dTg mice present with more abundant α Syn inclusion pathology than M20 mice (Fig. 2A). This finding was also confirmed with an antibody to p62/sequestasome-1, a marker of protein aggregation [57–59]. Semi-quantification of α Syn inclusion pathology stained with pSer129 antibody 81A or p62/sequestrasome-1 in α Syn PFF-injected 8-month or 10-month mice further revealed significantly more pathology in dTg mice compared to M20 mice (Fig. 2C). Quantification IRA OD for 5G4 staining revealed a significant increase in aggregated α Syn in dTg mice when compared to age-matched M20 mice, as well as an increase within the dTg cohort with age (Fig. 2C).

Induced α Syn inclusion pathology was often, but not exclusively, present in close proximity to A β plaques in





profiles resembling swollen neurites (arrows in Fig. 3A). The overall distribution of α Syn pathology was modified in the presence of A β , with a dramatic increase in pathology both anterior to and posterior of the injection site (Fig. 3B). These findings indicate that the hippocampal injection of α Syn PFFs in dTg mice produces a more rapidly spreading α Syn pathology than what occurs in mice expressing only human WT α Syn.

In both M20 and the dTg mice, a significant portion of α Syn pathology was localized to the neuropil where it is difficult to discern cellular origin. To further characterize pathology in the cortex, we co-stained sections from the dTg mice with antibodies to the neurofilament light chain (NFL) subunit (a neuronal marker) and α Syn (Fig. 3C). The majority of the induced α Syn pathology in cell bodies was present in neurons and the preponderance of α Syn neurites were also labeled for NFL (Fig. 3C).

Induction of pathological α Syn inclusions affects A β deposition

In order to test whether α Syn PFF-injection and pathology modulated the spread and severity of A β

plaques, we conducted an analysis on all cohorts of mice using an antibody that detects A β deposits (AB5). nTg and M20 cohorts did not exhibit plaque formation (Supplemental Figure 2), while both α Syn-injected and PBS-injected mice in the dTg and L85 cohorts showed extensive AB5-positive staining (Fig. 4A-C). Surprisingly, semi-quantitative analysis revealed that α Syn PFF-injection potentiated the accumulation of A β deposition in L85 mice, but not in dTg mice, despite dTg mice having extensive α Syn pathology (Fig. 4D). As expected for L85 mice, female mice tended to have a higher number of A β deposits relative to male mice, although by 10 months of age the difference was not statistically significant (Supplemental Figure 3). α Syn PFF injection appeared to increase A β deposition in both sexes of L85 mice (Supplemental Figure 3A). In the dTg mice, there was also a tendency for female mice to have higher numbers of deposits (Supplemental Figure 3B), but again, the difference was not statistically significant. The tendency for female dTg mice to have higher numbers of A β deposits was associated with a tendency for higher numbers of α Syn inclusions after PFF injection




Fig. 3 Phosphorylated α Syn-Positive Inclusions Contiguous to Cored A β Plaques. **A** IFA double labeling of phosphorylated α Syn-positive inclusions (EP1536Y; red) and A β (1–16) plaques (33.1.1; green) in the cortex, comparing age-matched dTg mice (10-month-old; 4 m.p.i.) injected with PBS or α Syn-PFFs. White arrows depict α Syn inclusions in close proximity to A β plaques. **B** Regional comparison of phosphorylated α Syn-positive pathology between age-matched, α Syn PFF-injected M20 and dTg cohorts. The level of α Syn pathology is illustrated by the color change from blue (minimum of total counted 81A positive inclusions) to orange (maximum of total counted 81A positive inclusions). Light gray indicates regions were not quantified during this study. **C** Double staining of α Syn PFF-injected 10-month-old (4 m.p.i.) dTg mice with anti-NFL (red) and anti- α Syn 81A (brown) antibodies in the cortex. Arrows indicate neuronal cell bodies labelled for NFL and positive for α Syn inclusions. Scale bars: 50 μ m


(Supplemental Figure 3C). Thus, although female L85 and dTg mice tended to have a greater burden of both A β and α Syn pathology, both sexes showed the same general response to injected α Syn PFFs.

Neuroinflammatory changes associated with induced α Syn inclusion pathology

To provide further insights into the pathological changes associated with prion-like induced α Syn inclusion pathology and A β deposition, changes in astrogliosis (GFAP) (Figs. 5 and 6) and microgliosis (Iba1) (Figs. 7 and 8) were investigated. Dramatic differences in glial activation responses were observed between different regions. To accommodate this regional variability, we segmented quantification into separate analyses of the retrosplenial

cortex, CA1 region of the hippocampus and the combined entorhinal/piriform cortex with the amygdalar region (Figs. 6 and 8).

In the nTg mice, GFAP reactivity was very low in the retrosplenial or entorhinal cortex (Fig. 5B). Surprisingly, nTg mice injected with PFFs displayed lower GFAP percent positivity in the CA1 region than age-matched, PBS-injected controls (Fig. 5B). M20 mice injected with α Syn PFF displayed increased astrogliosis in all brain regions examined (Figs. 5B and 6B). In L85 mice, regardless of whether injected with PFFs or PBS, activated astrocytes were primarily located adjacent to A β deposits. By contrast, in the dTg mice, PFF injection induced astrocytic activation that was significantly more severe than age-matched mice in L85, M20 and nTg cohorts; in all regions




that were measured (Figs. 5B and 6B). Because the level of A β pathology in the dTg mice injected with PFFs was lower than that of the L85 mice (Fig. 4C), we conclude that the more severe astrocytic response in the dTg mice was primarily driven by the induced α Syn pathology.

To examine microgliosis reactions, we stained sections with Iba1 antibodies. Overall, Iba1 immunoreactivity patterns paralleled that of GFAP (Figs. 7 and 8). In both the CA1 and entorhinal regions, microgliosis was significantly increased in 10-month dTg injected with α Syn PFFs compared to the PBS injected cohort. Similarly, as compared to nTg, L85, and M20 mice, Iba1 reactivity was more widespread in the dTg mice injected with PFFs (Figs. 7 and 8). These increases were observed in all three regions examined (retrosplenial cortex, CA1 hippocampal, and entorhinal cortex). Neither M20 nor L85 mice had a significant change in microglial response with injection type or aging despite exhibiting an increased protein aggregate burden (see Figs. 2C and 4D, respectively). Some of the Iba1 immunoreactivity may be marking infiltrating peripheral monocytes. Attempts to differentiate such cells with immune markers, such as

TMEM119 and CD68, were unsuccessful due to weak immunoreactivity for these proteins in our samples. The poor performance of the antibodies may be related to the ethanol fixation methods we use here to preserve certain α Syn epitopes.


Discussion

Our study has shown that the deposition of A β in the cortex and hippocampus creates an environment in which human α Syn pathology spreads more quickly and distributes across a greater area following prion-like seeding. The model created by our approach exhibits inclusions composed of WT human α Syn and human A β plaque pathology, allowing us to investigate the interactive sequelae associated with the progression of both types of protein aggregations. We observe an exacerbated inflammatory response in mice exhibiting both A β and α Syn pathology as compared to brains depositing these proteins individually. An important aspect of our model is that M20 mice do not develop α Syn pathology sans seeding, allowing us to delay the induction of synucleinopathy until after A β pathology had developed. At



the ages that we examined, no α Syn pathology was observed in dTg mice injected with PBS, indicating that the induced α Syn pathology was highly dependent upon seeding. Furthermore, human α Syn PFF injection did not induce pathology in nTg or L85 mice. Collectively, our findings demonstrate that prion-like propagation of human α Syn pathology spreads more quickly when induced in the presence of pre-existing A β pathology to produce a model that resembles human LBD.


Our findings are consistent with a recent study where mouse α Syn PFFs were injected in the 5xFAD model of A β deposition, finding a dramatic induction of mouse α Syn pathology when seeds were injected at ages in which pre-existing amyloid pathology was present [60]. The location of α Syn deposition in both models is remarkably similar, possibly related to the similarity in the distribution of A β pathology in the L85 and 5xFAD mice. Notably, human α Syn PFFs did not induce mouse



αSyn pathology in our L85 mice; a finding that is consistent with the premise of a ‘species barrier’ for prion-like proteins; a concept that hinges on the idea that human PFFs serve as a “seed” able to induce monomers in a solution to assume a β-sheet conformation, and eventual fibril elongation [61, 62], but require the appropriate secondary structural compatibilities for efficient conformational templating to occur [37, 63–65]. Human αSyn forms different quaternary structures than mouse αSyn, and this presumably inhibits the conformational templating of mouse αSyn [37, 66].

Previous studies in bigenic APP and αSyn mice had reported that Aβ deposition could exacerbate αSyn pathology without seeding [67]. In our dTg model, at the ages examined, we did not observe human αSyn inclusion pathology without seeding. The contrasting outcomes may be due to nature of the transgene expression or strains of mice. The effect that αSyn has on the deposition of Aβ has been examined in multiple studies with some studies demonstrating inhibitory activities of


αSyn on Aβ plaque formation [68] and others the opposite [69, 70]. For example, Clinton et al. crossed 3xTg-AD mice, which develop Aβ and tau pathology [71], with the M83 model of A53T synucleinopathy [35], finding mutant αSyn promoted Aβ aggregation [69]. In 2018, Khan et al. [70] published data suggesting that the levels of αSyn overexpression are inversely correlated with the amount of Aβ plaque accumulation in J20 APP transgenic mice crossed with Tg12.2 mice, which overexpress WT human αSyn. These studies reflect the initial condition dependent nature of Aβ and αSyn interactions. Clinton et al. [69] used hemizygous M83 mice, which develop αSyn pathology at 22–28 months [35], but reported seeing an increase in thioflavin S positive Aβ plaques at 12 months, before αSyn pathology would be present. In the second study mentioned, Khan et al. specifically measured a difference in amyloid burden during the preliminary stages of plaque deposition (aged animals to 6 month), comparing early amyloid deposition in the hippocampus [70]. Therefore, both of these studies



reported potential effects of non-aggregated α Syn on initial A β plaque deposition.

In our cohorts of dTg (L85/M20) mice we found no obvious difference in A β burden between dTg and L85 mice injected with PBS. The L85 model primarily presents with cored-neuritic deposits of A β and thus it would appear that this type of A β pathology is not greatly influenced by the presence of elevated levels of WT human α Syn. Similar to what was reported in 5xFAD mice injected with mouse α Syn PFFs [60], α Syn

PFF-injection in L85 mice appeared to increase plaque burden. By contrast, in the dTg mice, the injection of PFFs did not produce the same augmentation in A β pathology; however, we observed increased levels of both microglial and astrocytic activation after PFF injection within this cohort when compared to PBS-injected dTg mice. Many studies have emphasized the importance of gliosis in the attenuation of A β plaque deposition. Previous work by Chakrabarty et al. has shown that decreased neuroinflammation, brought on by anti-inflammatory



cytokines, such as Interleukin-10 or Interleukin-4, suppresses microglial phagocytosis of A β plaques and worsens cognitive deficits in APP mice [72, 73], whereas upregulation of the proinflammatory cytokines, Interleukin-6, Interferon γ or Tumor Necrosis Factor α , results in a reduction of A β plaque deposition [52, 74, 75]. Shaftel et al. demonstrated that hippocampal overexpression of the proinflammatory cytokine, IL-1 β , results in a reduction of amyloid pathology in APP mice [76]. Taken together, these data demonstrate a complicated interplay between different pathologies that appear to influence the overall evolution of pathology.

As α Syn was initially described as the non-amyloid component of amyloid plaques (NACP) [77], the direct interactions and copolymerization of α Syn and A β have been reported in many in vitro studies [67, 78–83]. In fact, PFFs have been shown to be able to nucleate A β aggregation [84]; however the literature on this topic is complicated. In 2020, Candreva et al., demonstrated that α Syn monomers and oligomers co-assemble with A β , stabilizing A β oligomers and thus preventing A β fibrillization, whereas α Syn fibrils did not change fibrillization

[83]. Furthermore, the effect of α Syn on A β fibrillization was lost when aggregation studies were seeded with pre-formed A β fibrils [83]. Taken together, these results hint towards a possible sequence-dependent phenomenon, where progression of pathology depends on which protein first began forming pathological inclusions. The process is further complicated by inflammatory changes that each type of pathology may also induce.

The ability of α Syn and A β to copolymerize suggests a potential mechanism in which pre-existing A β pathology could augment α Syn seeding. It is possible that α Syn PFFs are able to directly interact with A β deposits at the time of injection to stabilize the α Syn seeds in a manner that potentiates seeding. While it is conceivable that these exogenous α Syn PFFs were able to seed additional A β plaques in L85 mice, our measurements, recorded at the end stage of the disease, did not detect an obvious concentration of α Syn inclusions near A β deposits. It is also possible that neuronal hyperactivation resulting from, or even preceding, A β plaque formation in APP mouse models [85–87], promoted PFF neuronal uptake. Elevated neuronal activity can significantly influence

neuronal α Syn cellular uptake and release [88, 89]. Consistent with this notion, Wu et al. [90] recently demonstrated that increasing neuronal activity in hippocampal and midbrain slice cultures from 5xFAD mice treated with α Syn PFFs enhanced seeding of α Syn inclusions.

Conclusions

Clinical evidence points to a preponderance of co-pathologies between prionogenic proteins that are correlated to neurodegenerative diseases [10, 11, 13–16, 18, 28], however the cause-effect relationships are difficult to ascertain in human post-mortem studies, and is better determined using animal experimental models. Nevertheless, the human genetic and pathological findings that patients with genetic alterations in the *APP*, *PSEN1*, and *PSEN2* genes that drive A β deposition, also predispose patients to develop α Syn pathology, provide strong evidence of collusion between aberrant A β accumulation and α Syn, in the pathobiology of neurodegenerative diseases [12, 24–27]. This clinical revelation is rapidly being translated into animal models for further exploration, with many research teams developing multi-malprotein overexpression models to analyze how different combinations of pathological proteins can affect the progression of disease [60, 67–69, 91, 92]. Therefore, our intention in this study was primarily to create a novel and accurate mouse model that closely recapitulates authentic conditions in neurodegenerative diseases. In summary, we present a humanized model of AD/LBD, in which pre-existing A β deposition augments the seeding activity of human α Syn PFFs to produce pathology resembling AD/LBD. Our novel model provides a new platform to examine pathogenic protein interactions between human α Syn and A β , and the in vivo assessment of therapeutic interventions.

Abbreviations

AD: Alzheimer's Disease; APP: Amyloid precursor protein; A β : Amyloid beta; α Syn: Alpha-synuclein; CNS: Central nervous system; CSF: Cerebrospinal fluid; dTg: Double transgenic; GFAP: Glial fibrillary acidic protein; HIER: Heat-induced epitope retrieval; IRA: Immunoreactive Area; Iba1: Ionized calcium binding adaptor molecule 1; IFA: Immunofluorescence analysis; IFN- γ : Interferon- γ ; IHC: Immunohistochemistry; IL-10: Interleukin-10; IL-6: Interleukin-6; LB: Lewy bodies; LBD: Lewy Body Dementia; LN: Lewy neurites; m.p.i.: Months post-injection; MSA: Multiple Systems Atrophy; NDDs: Neurodegenerative disorders; NFL: Neurofilament light chain; nTg: Non-transgenic; OD: Optical Density; PD: Parkinson's disease; PDD: Parkinson's Disease with Dementia; PFF: Preformed fibrils; PS1: Presenilin 1; SNpc: Substantia Nigra pars compacta; SQST M1: Sequestrasome1; TNF α : Tumor Necrosis Factor α

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s13024-021-00486-9>.

Additional file 1: Supplemental Figure 1. L85 and nTg Mice do not Exhibit α Syn Pathology Despite α Syn PFF-injection. Representative images showing immunohistochemistry of tissue sections stained using

antibodies specific for phosphorylated α Syn (81A), α Syn (2H6) and p62/sequestrasome-1 from α Syn PFF-injected nTg and α Syn PFF-injected L85 mice in the 10-month-old (4 m.p.i.) cohort. No inclusions of endogenous α Syn were observed in these cohorts. Scale bar: 100 μ m. The images shown are representative of independent IHC stains from all animals.

Supplemental Figure 2. M20 and nTg Mice do not Exhibit A β Pathology. Representative images showing IHC using antibodies specific for A β (A85), on sections from 10-month-old (4 m.p.i.) α Syn PFF-injected nTg and M20 mice. No A β plaque pathology was observed in these cohorts. Scale bar: 200 μ m. The images shown are representative of independent IHC stains from all animals. **Supplemental Figure 3.** Analysis of A β and α Syn pathology by sex. Semi-quantitative data for A β deposits and α Syn pathology levels in 10-month-old L85 and dTg mice are graphed according to sex. Female, PBS-injected L85 and dTg mice tended to have higher numbers of A β deposits (**A-B**). There was no statistically significant difference between males and females with either A β plaque deposition or α Syn inclusion pathology (**A-C**); therefore, all quantitative analyses combined data from both sexes.

Authors' contributions

Conceived and designed the experiments: GML, JSD, CR, BIG, DRB. Performed the experiments: GML, JSD, CR, KMG, SEF, YX. Analyzed the data: GML, JSD, YX, BIG, DRB. Wrote the manuscript: GML, JSD, BIG, DRB. All authors read and approved the final manuscript.

Funding

This work was supported by grants from the National Institute on Aging (P50AG047266) and the National Institute of Neurological Disorders and Stroke (R01NS089022, R01NS100876) and (T32 NS082168) (JSD).

Availability of data and materials

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

All procedures were performed according to the National Institute of Health Guide for the Care and Use of Experimental Animals and were approved by the University of Florida Institutional Animal Care and Use Committee.

Consent for publication

Not applicable.

Competing interests

We declare no conflict of interest in this manuscript.

Author details

¹Department of Neuroscience, College of Medicine, University of Florida, Gainesville, Florida 32610, USA. ²Center for Translational Research in Neurodegenerative Disease, College of Medicine, University of Florida, Gainesville, Florida 32610, USA. ³McKnight Brain Institute, College of Medicine, University of Florida, BMS J499, J483/CTRND, 1275 Center Drive, Gainesville, FL 32610, USA.

Received: 15 March 2021 Accepted: 19 August 2021

Published online: 09 September 2021

References

- Eisenberg D, Jucker M. The amyloid state of proteins in human diseases. *Cell*. 2012;148(6):1188–203. <https://doi.org/10.1016/j.cell.2012.02.022>.
- Prusiner SB. A unifying role for prions in neurodegenerative diseases. *Science*. 2012;336(6088):1511–3. <https://doi.org/10.1126/science.1222951>.
- Ayers JI, Prusiner SB. Prion protein — mediator of toxicity in multiple proteinopathies. *Nat Rev Neurol*. 2020;16(4):1–2. <https://doi.org/10.1038/s41582-020-0332-8>.
- Hansen LA, Masliah E, Galasko D, Terry RD. Plaque-only alzheimer disease is usually the lewy body variant, and vice versa. *J Neuropathol Exp Neurol*. 1993;52(6):648–54. <https://doi.org/10.1097/00005072-199311000-00012>.

5. Hansen L, Salmon D, Galasko D, Masliah E, Katzman R, Deteresa R, et al. The lewy body variant of alzheimer's disease: a clinical and pathologic entity. *Neurology*. 1990;40(1):1–8. <https://doi.org/10.1212/wnl.40.1.1>.
6. Samuel W, Galasko D, Masliah E, Hansen LA. Neocortical Lewy body counts correlate with dementia in the Lewy body variant of Alzheimer's disease. *J Neuropathol Exp Neurol*. 1996;55(1):44–52. <https://doi.org/10.1097/00005072-199601000-00005>.
7. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. *Neurology*. 1996;47(5):1113–24. <https://doi.org/10.1212/WNL.47.5.1113>.
8. Galasko D, Hansen LA, Katzman R, Wiederholt W, Masliah E, Terry R, et al. Clinical-neuropathological correlations in Alzheimer's disease and related dementias. *Arch Neurol*. 1994;51(9):888–95. <https://doi.org/10.1001/archneur.1994.00540210060013>.
9. Perry RH, Irving D, Tomlinson BE. Lewy body prevalence in the aging brain: relationship to neuropsychiatric disorders, Alzheimer-type pathology and catecholaminergic nuclei. *J Neurol Sci*. 1990;100(1-2):223–33. [https://doi.org/10.1016/0022-510X\(90\)90037-N](https://doi.org/10.1016/0022-510X(90)90037-N).
10. Irwin DJ, Grossman M, Weintraub D, Hurtig HI, Duda JE, Xie SX, et al. Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. *Lancet Neurol*. 2017;16(1):55–65. [https://doi.org/10.1016/S1474-4422\(16\)30291-5](https://doi.org/10.1016/S1474-4422(16)30291-5).
11. Irwin DJ, Lee VMY, Trojanowski JQ. Parkinson's disease dementia: convergence of α -synuclein, tau and amyloid- β pathologies. *Nat Rev Neurosci*. 2013;14(9):626–36. <https://doi.org/10.1038/nrn3549>.
12. Hamilton RL. Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using α -synuclein immunohistochemistry. *Brain Pathol*. 2000;10(3):378–84. <https://doi.org/10.1111/j.1750-3639.2000.tb00269.x>.
13. Smith C, Malek N, Grosset K, Cullen B, Gentleman S, Grosset DG. Neuropathology of dementia in patients with Parkinson's disease: a systematic review of autopsy studies. *J Neurol Neurosurg Psychiatry*. 2019;90:1234–43. <https://doi.org/10.1136/jnnp-2019-321111>.
14. Kalaitzakis ME, Walls AJ, Pearce RKB, Gentleman SM. Striatal A β peptide deposition mirrors dementia and differentiates DLB and PDD from other parkinsonian syndromes. *Neurobiol Dis*. 2011;41(2):377–84. <https://doi.org/10.1016/j.nbd.2010.10.005>.
15. Walker L, McAleese KE, Thomas AJ, Johnson M, Martin-Ruiz C, Parker C, et al. Neuropathologically mixed Alzheimer's and Lewy body disease: burden of pathological protein aggregates differs between clinical phenotypes. *Acta Neuropathol*. 2015;129(5):729–48. <https://doi.org/10.1007/s00401-015-1406-3>.
16. Jellinger KA. Striatal β -amyloid deposition in Parkinson disease with dementia. *J Neuropathol Exp Neurol*. 2008;67(5):484–484. <https://doi.org/10.1097/NEN.0b013e3181713cb1>.
17. Compta Y, Pereira JB, Ríos J, Ibarretxe-Bilbao N, Junqué C, Bargalló N, et al. Combined dementia-risk biomarkers in Parkinson's disease: a prospective longitudinal study. *Park Relat Disord*. 2013;19(8):717–24. <https://doi.org/10.1016/j.parkreldis.2013.03.009>.
18. Compta Y, Parkkinen L, O'Sullivan SS, Vandrovicova J, Holton JL, Collins C, et al. Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? *Brain*. 2011;134(5):1493–505. <https://doi.org/10.1093/brain/awr031>.
19. Armstrong RA, Cairns NJ, Lantos PL. β -Amyloid (A β) deposition in the medial temporal lobe of patients with dementia with Lewy bodies. *Neurosci Lett*. 1997;227(3):193–6. [https://doi.org/10.1016/S0304-3940\(97\)00343-1](https://doi.org/10.1016/S0304-3940(97)00343-1).
20. Jendroska K, Lees AJ, Poewe W, Daniel SE. Amyloid β -peptide and the dementia of Parkinson's disease. *Mov Disord*. 1996;11(6):647–53. <https://doi.org/10.1002/mds.870110609>.
21. Trojanowski JQ, Goedert M, Iwatsubo T, Lee VMY. Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia. *Cell Death Differ*. 1998;5(10):832–7. <https://doi.org/10.1038/sj.cdd.4400432>.
22. Donaghy PC, McKeith IG. The clinical characteristics of dementia with Lewy bodies and a consideration of prodromal diagnosis. *Alzheimers Res Ther*. 2014;6(4):46. <https://doi.org/10.1186/alzrt274>.
23. Perry RH, Irving D, Blessed G, Fairbairn A, Perry EK. Senile dementia of Lewy body type. A clinically and neuropathologically distinct form of Lewy body dementia in the elderly. *J Neurol Sci*. 1990;95(2):119–39. [https://doi.org/10.1016/0022-510X\(90\)90236-G](https://doi.org/10.1016/0022-510X(90)90236-G).
24. Lippa CF, Fujiwara H, Mann DMA, Giasson B, Baba M, Schmidt ML, et al. Lewy bodies contain altered α -synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. *Am J Pathol*. 1998;153(5):1365–70. [https://doi.org/10.1016/S0002-9440\(10\)65722-7](https://doi.org/10.1016/S0002-9440(10)65722-7).
25. Carmona S, Hardy J, Guerreiro R. The genetic landscape of Alzheimer disease. *Handb Clin Neurol*. 2018;148:395–408. <https://doi.org/10.1016/B978-0-444-64076-5.00026-0>.
26. Scahill RI, Ridgway GR, Bartlett JW, Barnes J, Ryan NS, Mead S, et al. Genetic influences on atrophy patterns in familial Alzheimer's disease: a comparison of APP and PSEN1 mutations. *J Alzheimers Dis*. 2013;35(1):199–212. <https://doi.org/10.3233/JAD-121255>.
27. Hardy J. The discovery of Alzheimer-causing mutations in the APP gene and the formulation of the "amyloid cascade hypothesis". *FEBS J*. 2017;284(7):1040–4. <https://doi.org/10.1111/febs.14004>.
28. McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies. *Neurology*. 2017;89(1):88–100. <https://doi.org/10.1212/WNL.0000000000004058>.
29. Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, et al. National Institute on Aging-Alzheimer's association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. *Acta Neuropathol*. 2012;123(1):1–11. <https://doi.org/10.1007/s00401-011-0910-3>.
30. Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al. National Institute on Aging-Alzheimer's association guidelines for the neuropathologic assessment of Alzheimer's disease. *Alzheimers Dement*. 2012;8(1):1–13. <https://doi.org/10.1016/j.jalz.2011.10.007>.
31. Giasson BI, Lee VMY, Trojanowski JQ, M-Y Lee V, Trojanowski JQ. Interactions of Amyloidogenic proteins. *NeuroMolecular Med*. 2003;4(1-2):49–58. <https://doi.org/10.1385/NMM:4:1-2:49>.
32. Sacino AN, Brooks M, McGarvey NH, McKinney AB, Thomas MA, Levites Y, et al. Induction of CNS α -synuclein pathology by fibrillar and non-amyloidogenic recombinant α -synuclein. *Acta Neuropathol Commun*. 2014;2(1):38. <https://doi.org/10.1186/2051-5960-1-38>.
33. Ayers JL, Brooks MM, Rutherford NJ, Howard JK, Sorrentino ZA, Riffe CJ, et al. Robust central nervous system pathology in transgenic mice following peripheral injection of α -Synuclein fibrils. *J Virol*. 2017;91(2):e02095–16. <https://doi.org/10.1128/jvi.02095-16>.
34. Rutherford NJ, Dhillion JKS, Riffe CJ, Howard JK, Brooks M, Giasson BI. Comparison of the in vivo induction and transmission of α -synuclein pathology by mutant α -synuclein fibril seeds in transgenic mice. *Hum Mol Genet*. 2017;26(24):4906–15. <https://doi.org/10.1093/hmg/ddx371>.
35. Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VMY. Neuronal α -synucleinopathy with severe movement disorder in mice expressing A53T human α -synuclein. *Neuron*. 2002;34(4):521–33. [https://doi.org/10.1016/S0896-6273\(02\)00682-7](https://doi.org/10.1016/S0896-6273(02)00682-7).
36. Sacino AN, Brooks M, Shaw G, Golde TE, Giasson BI, McKinney AB, et al. Brain injection of α -Synuclein induces multiple proteinopathies, gliosis, and a neuronal injury marker. *J Neurosci*. 2014;34(37):12368–78. <https://doi.org/10.1523/JNEUROSCI.2102-14.2014>.
37. Sorrentino ZA, Brooks MMT, Hudson V, Rutherford NJ, Golde TE, Giasson BI, et al. Intrastriatal injection of α -synuclein can lead to widespread synucleinopathy independent of neuroanatomic connectivity. *Mol Neurodegener*. 2017;12(1):40. <https://doi.org/10.1186/s13024-017-0182-z>.
38. Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, Borchelt DR. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. *Biomol Eng*. 2001;17(6):157–65. [https://doi.org/10.1016/S1389-0344\(01\)00067-3](https://doi.org/10.1016/S1389-0344(01)00067-3).
39. Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, et al. Mutant presenilins specifically elevate the levels of the 42 residue β -amyloid peptide in vivo: evidence for augmentation of a 42-specific γ secretase. *Hum Mol Genet*. 2004;13(2):159–70. <https://doi.org/10.1093/hmg/ddh019>.
40. Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VMY. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. *Neuron*. 2002;34(4):521–33. [https://doi.org/10.1016/S0896-6273\(02\)00682-7](https://doi.org/10.1016/S0896-6273(02)00682-7).
41. Emmer KL, Waxman EA, Covy JP, Giasson BI. E46K human α -synuclein transgenic mice develop lewy-like and tau pathology associated with age-dependent, detrimental motor impairment. *J Biol Chem*. 2011;286(40):35104–18. <https://doi.org/10.1074/jbc.M111.247965>.
42. Borchelt DR, Davis J, Fischer M, Lee MK, Slunt HH, Ratovitski T, et al. A vector for expressing foreign genes in the brains and hearts of transgenic

- mice. *Genet Anal - Biomol Eng.* 1996;13(6):159–63. [https://doi.org/10.1016/S1050-3862\(96\)00167-2](https://doi.org/10.1016/S1050-3862(96)00167-2).
43. Greenbaum EA, Graves CL, Mishizen-Eberz AJ, Lupoli MA, Lynch DR, Englander SW, et al. The E46K mutation in α -synuclein increases amyloid fibril formation. *J Biol Chem.* 2005;280(9):7800–7. <https://doi.org/10.1074/jbc.M411638200>.
 44. Giasson BI, Murray IVJ, Trojanowski JQ, Lee VMY. A hydrophobic stretch of 12 amino acid residues in the middle of α -Synuclein is essential for filament assembly. *J Biol Chem.* 2001;276(4):2380–6. <https://doi.org/10.1074/jbc.M008919200>.
 45. Crystal AS, Giasson BI, Crowe A, Kung MP, Zhuang ZP, Trojanowski JQ, et al. A comparison of amyloid fibrillogenesis using the novel fluorescent compound K114. *J Neurochem.* 2003;86(6):1359–68. <https://doi.org/10.1046/j.1471-4159.2003.01949.x>.
 46. Sorrentino ZA, Xia Y, Funk C, Riffe CJ, Rutherford NJ, Ceballos Diaz C, et al. Motor neuron loss and neuroinflammation in a model of α -synuclein-induced neurodegeneration. *Neurobiol Dis.* 2018;120:98–106. <https://doi.org/10.1016/j.nbd.2018.09.005>.
 47. Duda JE, Giasson BI, Gur TL, Montine TJ, Robertson D, Biaggioni J, et al. Immunohistochemical and biochemical studies demonstrate a distinct profile of α -Synuclein permutations in multiple system atrophy. *J Neuropathol Exp Neurol.* 2000;59(9):830–41. <https://doi.org/10.1093/jnen/59.9.830>.
 48. Waxman EA, Duda JE, Giasson BI. Characterization of antibodies that selectively detect α -synuclein in pathological inclusions. *Acta Neuropathol.* 2008;116(1):37–46. <https://doi.org/10.1007/s00401-008-0375-1>.
 49. Dhillon J-KS, Riffe C, Moore BD, Ran Y, Chakrabarty P, Golde TE, et al. A novel panel of α -synuclein antibodies reveal distinctive staining profiles in synucleinopathies. *PLoS One.* 2017;12(9):e0184731. <https://doi.org/10.1371/journal.pone.0184731>.
 50. Sorrentino ZA, Goodwin MS, Riffe CJ, Dhillon JKS, Xia Y, Gorion KM, et al. Unique α -synuclein pathology within the amygdala in Lewy body dementia: implications for disease initiation and progression. *Acta Neuropathol Commun.* 2019;7(1):142. <https://doi.org/10.1186/s40478-019-0787-2>.
 51. Uchihara T, Giasson BI. Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. *Acta Neuropathol.* 2016;131(1):49–73. <https://doi.org/10.1007/s00401-015-1485-1>.
 52. Chakrabarty P, Jansen-West K, Beccard A, Ceballos-Diaz C, Levites Y, Verbeeck C, et al. Massive gliosis induced by interleukin-6 suppresses A β deposition in vivo: evidence against inflammation as a driving force for amyloid deposition. *FASEB J.* 2010;24(2):548–59. <https://doi.org/10.1096/fj.09-141754>.
 53. Kovacs GG, Wagner U, Dumont B, Pikkarainen M, Osman AA, Streichenberger N, et al. An antibody with high reactivity for disease-associated α -synuclein reveals extensive brain pathology. *Acta Neuropathol.* 2012;124(1):37–50. <https://doi.org/10.1007/s00401-012-0964-x>.
 54. Lloyd GM, Trejo-Lopez JA, Xia Y, McFarland KN, Lincoln SJ, Ertekin-Taner N, et al. Prominent amyloid plaque pathology and cerebral amyloid angiopathy in APP V717I (London) carrier - phenotypic variability in autosomal dominant Alzheimer's disease. *Acta Neuropathol Commun.* 2020; 8(1):31. <https://doi.org/10.1186/s40478-020-0891-3>.
 55. Garcia-Alloza M, Robbins EM, Zhang-Nunes SX, Purcell SM, Betensky RA, Raju S, et al. Characterization of amyloid deposition in the APP^{swe}/PS1^{dE9} mouse model of Alzheimer disease. *Neurobiol Dis.* 2006;24(3):516–24. <https://doi.org/10.1016/j.nbd.2006.08.017>.
 56. Jankowsky JL, Slunt HH, Gonzales V, Jenkins NA, Copeland NG, Borchelt DR. APP processing and amyloid deposition in mice haplo-insufficient for presenilin 1. *Neurobiol Aging.* 2004;25(7):885–92. <https://doi.org/10.1016/j.neurobiolaging.2003.09.008>.
 57. Kuusisto E, Parkkinen L, Alafuzoff I. Morphogenesis of Lewy bodies: dissimilar incorporation of α -Synuclein, ubiquitin, and p62. *J Neuropathol Exp Neurol.* 2003;62(12):1241–53. <https://doi.org/10.1093/jnen/62.12.1241>.
 58. Rusten TE, Stenmark H. P62, an autophagy hero or culprit? *Nat Cell Biol.* 2010;12(3):207–9. <https://doi.org/10.1038/ncb0310-207>.
 59. Komatsu M, Kurokawa H, Waguri S, Taguchi K, Kobayashi A, Ichimura Y, et al. The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. *Nat Cell Biol.* 2010; 12(3):213–23. <https://doi.org/10.1038/ncb2021>.
 60. Bassil F, Brown HJ, Pattabhiraman S, Zhang B, Trojanowski JQ, Lee VMY, et al. Amyloid-Beta (A β) plaques promote seeding and spreading of alpha-Synuclein and tau in a mouse model of Lewy body disorders with A β pathology. *Neuron.* 2020;105(2):1–16. <https://doi.org/10.1016/j.neuron.2019.10.010>.
 61. Pinotsi D, Buell AK, Galvagnion C, Dobson CM, Kaminski Schierle GS, Kaminski CF. Direct observation of heterogeneous amyloid fibril growth kinetics via two-color super-resolution microscopy. *Nano Lett.* 2014;14(1): 339–45. <https://doi.org/10.1021/nl4041093>.
 62. Lansbury PT. Structural neurology: are seeds at the root of neuronal degeneration? *Neuron.* 1997;19(6):1151–4. [https://doi.org/10.1016/S0896-6273\(00\)80406-7](https://doi.org/10.1016/S0896-6273(00)80406-7).
 63. Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury PT, et al. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. *Proc Natl Acad Sci U S A.* 2000; 97(2):571–6. <https://doi.org/10.1073/pnas.97.2.571>.
 64. Luk KC, Covell DJ, Kehm VM, Zhang B, Song IY, Byrne MD, et al. Molecular and biological compatibility with host alpha-Synuclein influences fibril pathogenicity. *Cell Rep.* 2016;16(12):3373–87. <https://doi.org/10.1016/j.celrep.2016.08.053>.
 65. Masuda-Suzukake M, Nonaka T, Hosokawa M, Oikawa T, Arai T, Akiyama H, et al. Prion-like spreading of pathological α -synuclein in brain. *Brain.* 2013; 136(4):1128–38. <https://doi.org/10.1093/brain/awt037>.
 66. Hwang S, Fricke P, Zinke M, Giller K, Wall JS, Riedel D, et al. Comparison of the 3D structures of mouse and human α -synuclein fibrils by solid-state NMR and STEM. *J Struct Biol.* 2019;206(1):43–8. <https://doi.org/10.1016/j.jsb.2018.04.003>.
 67. Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, Hashimoto M, et al. β -Amyloid peptides enhance α -synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. *Proc Natl Acad Sci U S A.* 2001;98(21):12245–50. <https://doi.org/10.1073/pnas.211412398>.
 68. Bachhuber T, Katzmarski N, McCarter JF, Loreth D, Tahirovic S, Kamp F, et al. Inhibition of amyloid- β plaque formation by α -synuclein. *Nat Med.* 2015; 21(7):802–7. <https://doi.org/10.1038/nm.3885>.
 69. Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ, LaFerla FM. Synergistic interactions between A β , tau, and α -synuclein: acceleration of neuropathology and cognitive decline. *J Neurosci.* 2010;30(21):7281–9. <https://doi.org/10.1523/JNEUROSCI.0490-10.2010>.
 70. Khan SS, LaCroix M, Boyle G, Sherman MA, Brown JL, Amar F, et al. Bidirectional modulation of Alzheimer phenotype by alpha-synuclein in mice and primary neurons. *Acta Neuropathol.* 2018;136(4):589–605. <https://doi.org/10.1007/s00401-018-1886-z>.
 71. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kaye R, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular A β and synaptic dysfunction. *Neuron.* 2003;39(3):409–21. [https://doi.org/10.1016/S0896-6273\(03\)00434-3](https://doi.org/10.1016/S0896-6273(03)00434-3).
 72. Chakrabarty P, Li A, Ceballos-Diaz C, Eddy JA, Funk CC, Moore B, et al. IL-10 alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior. *Neuron.* 2015;85(3):519–33. <https://doi.org/10.1016/j.neuron.2014.11.020>.
 73. Chakrabarty P, Tianbai L, Herring A, Ceballos-Diaz C, Das P, Golde TE. Hippocampal expression of murine IL-4 results in exacerbation of amyloid deposition. *Mol Neurodegener.* 2012;7(1):36. <https://doi.org/10.1186/1750-1326-7-36>.
 74. Chakrabarty P, Cellallos-Diaz C, Beccard A, Janus C, Dickson D, Golde TE, Das P. IFN-gamma promotes complement expression and attenuates amyloid plaque deposition in amyloid beta precursor protein transgenic mice. *J Immunol.* 2010;184(9):5333–43. <https://doi.org/10.4049/jimmunol.0903382>.
 75. Chakrabarty P, Herring A, Ceballos-Diaz C, Das P, Golde TE. Hippocampal expression of murine TNF results in attenuation of amyloid deposition in vivo. *Mol Neurodegener.* 2011;6(1):16. <https://doi.org/10.1186/1750-1326-6-16>.
 76. Shaftel SS, Kyrkanides S, Olschowka JA, Miller JNH, Johnson RE, O'Banion MK. Sustained hippocampal IL-1 β overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. *J Clin Invest.* 2007;117(6):1595–604. <https://doi.org/10.1172/JCI31450>.
 77. Ueda K, Fukushima H, Masliah E, Xia Y, Iwai A, Yoshimoto M, et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. *Neurobiology.* 1993;90:11282–6.
 78. Jensen PH, Sorensen ES, Petersen TE, Gliemann J, Rasmussen LK. Residues in the synuclein consensus motif of the α -synuclein fragment, NAC, participate in transglutaminase-catalysed cross-linking to Alzheimer-disease amyloid

- β A4 peptide. *Biochem J.* 1995;310(1):91–4. <https://doi.org/10.1042/bj3100091>.
79. Jensen PH, Højrup P, Hager H, Nielsen MS, Jacobsen L, Olesen OF, et al. Binding of A β to α - and β -synucleins: identification of segments in α -synuclein/NACP precursor that bind A β and NACP. *Biochem J.* 1997;323(2):539–46. <https://doi.org/10.1042/bj3230539>.
80. Yoshimoto M, Iwai A, Kang D, Otero DAC, Xia Y, Saitoh T. NACP, the precursor protein of the non-amyloid β /A4 protein (A β) component of Alzheimer disease amyloid, binds A β and stimulates A β aggregation. *Proc Natl Acad Sci U S A.* 1995;92(20):9141–5. <https://doi.org/10.1073/pnas.92.20.9141>.
81. Ono K, Takahashi R, Ikeda T, Yamada M. Cross-seeding effects of amyloid β -protein and α -synuclein. *J Neurochem.* 2012;122(5):883–90. <https://doi.org/10.1111/j.1471-4159.2012.07847.x>.
82. Tsigelny IF, Crews L, Desplats P, Shaked GM, Sharikov Y, Mizuno H, et al. Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases. *PLoS One.* 2008;3(9):e3135. <https://doi.org/10.1371/journal.pone.0003135>.
83. Candreva J, Chau E, Rice ME, Kim JR. Interactions between soluble species of β -amyloid and α -Synuclein promote oligomerization while inhibiting fibrillization. *Biochemistry.* 2020;59(4):425–35. <https://doi.org/10.1021/acs.biochem.9b00655>.
84. Chia S, Flagmeier P, Habchi J, Lattanzi V, Linse S, Dobson CM, et al. Monomeric and fibrillar α -synuclein exert opposite effects on the catalytic cycle that promotes the proliferation of A β 42 aggregates. *Proc Natl Acad Sci U S A.* 2017;114(30):8005–10. <https://doi.org/10.1073/pnas.1700239114>.
85. Busche MA, Konnerth A. Impairments of neural circuit function in Alzheimer's disease. *Philos Trans R Soc B Biol Sci.* 2016;371(1700):20150429. <https://doi.org/10.1098/rstb.2015.0429>.
86. Busche MA, Eichhoff G, Adelsberger H, Abramowski D, Wiederhold KH, Haass C, et al. Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer's disease. *Science.* 2008;321(5896):1686–9. <https://doi.org/10.1126/science.1162844>.
87. Goutagny R, Gu N, Cavanagh C, Jackson J, Chabot JG, Quirion R, et al. Alterations in hippocampal network oscillations and theta-gamma coupling arise before A β overproduction in a mouse model of Alzheimer's disease. *Eur J Neurosci.* 2013;37(12):1896–902. <https://doi.org/10.1111/ejn.12233>.
88. Yamada K, Iwatsubo T. Extracellular α -synuclein levels are regulated by neuronal activity. *Mol Neurodegener.* 2018;13(1):9. <https://doi.org/10.1186/s13024-018-0241-0>.
89. Gureviciene I, Gurevicius K, Tanila H. Role of α -synuclein in synaptic glutamate release. *Neurobiol Dis.* 2007;28(1):83–9. <https://doi.org/10.1016/j.nbd.2007.06.016>.
90. Wu Q, Shaikh MA, Meymand ES, Zhang B, Luk KC, Trojanowski JQ, et al. Neuronal activity modulates alpha-synuclein aggregation and spreading in organotypic brain slice cultures and in vivo. *Acta Neuropathol.* 2020;140(6):831–49. <https://doi.org/10.1007/s00401-020-02227-6>.
91. Croft CL, Cruz PE, Ryu DH, Ceballos-Diaz C, Strang KH, Woody BM, et al. rAAV-based brain slice culture models of Alzheimer's and Parkinson's disease inclusion pathologies. *J Exp Med.* 2019;216(3):539–55. <https://doi.org/10.1084/jem.20182184>.
92. Williams T, Sorrentino Z, Weinrich M, Giasson BI, Chakrabarty P. Differential cross-seeding properties of tau and α -synuclein in mouse models of tauopathy and synucleinopathy. *Brain Commun.* 2020;2(2). <https://doi.org/10.1093/braincomms/fcaa090>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

